NCT00033644 is a Phase 2 clinical trial of sargramostim in Sarcoma, sponsored by Gynecologic Oncology Group.

Who is sponsoring NCT00033644?

NCT00033644 is sponsored by Gynecologic Oncology Group.

What drugs are being tested in NCT00033644?

Interventions in NCT00033644: sargramostim, cisplatin, dacarbazine, doxorubicin hydrochloride, mitomycin C.

Is NCT00033644 still recruiting?

NCT00033644 is currently terminated. Last updated 10 April 2013.

Last reviewed 2013-04-10 · How we verify

NCT00033644

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus

Terminated Phase 2 Last updated 10 April 2013

What this trial tests

Phase 2 trial testing sargramostim in Sarcoma. Terminated before completion.

Timeline

1 March 2002

Primary endpoint
1 October 2005

Quick facts

Lead sponsor	Gynecologic Oncology Group
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Primary purpose	treatment
Start date	1 March 2002
Primary completion	1 October 2005
Sites	21 locations across United States, Norway

Drugs / interventions tested

sargramostim (SARGRAMOSTIM) — full drug profile →
cisplatin (cisplatin) — full drug profile →
dacarbazine (dacarbazine) — full drug profile →
doxorubicin hydrochloride — full drug profile →
mitomycin C

Conditions studied

Sarcoma — all drugs for Sarcoma →

Sponsor

Gynecologic Oncology Group — full company profile →

Who can join

18 and older, female only, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the uterus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of sargramostim

Trials testing the same drug.

NCT05366283 — Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenou · Phase 1 · completed
NCT03790670 — Biomarker Assessments of Leukine During Treatment of Parkinson's Disease · Phase 1 · completed
NCT02250014 — The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer · Phase 1 · completed
NCT01882010 — Leukine (Sargramostim) for Parkinson's Disease · Phase 1 · completed
NCT01536054 — Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Perit · Phase 1 · completed

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other Gynecologic Oncology Group trials

Trials by the same sponsor.

NCT04393285 — Abemaciclib and Letrozole to Treat Endometrial Cancer · Phase 2 · active not recruiting
NCT03673124 — Ribociclib and Letrozole Treatment in Ovarian Cancer · Phase 2 · active not recruiting
NCT02065687 — Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent · Phase 2, PHASE3 · unknown
NCT01720173 — Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · Phase 2 · completed
NCT01406769 — Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stag · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00033644 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gynecologic Oncology Group
Last refreshed: 10 April 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00033644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing